EuroPCR 2022 | Should Revascularization Be Performed Before TAVR in Patients with Stable Coronary Disease?

Currently, the American and European guidelines recommend coronary angioplasty in patients with severe aortic stenosis with lesions >70% (Class IIa) who will undergo transcatheter aortic valve replacement (TAVR). However, the benefit of performing a revascularization in these patients is still uncertain.

EuroPCR 2022

This prospective multicenter study included 2025 patients divided into two groups: complete revascularization (N = 1310) and incomplete revascularization (N = 715).

The primary endpoint (PEP) was all-cause mortality at 2 years. The study also included an additional PEP of all-cause mortality, stroke, acute myocardial infarction (AMI), or readmission for heart failure (HF) at 2 years. The secondary endpoint (SEP) was stroke, AMI, readmission for HF, and unplanned angioplasty at 2 years.

Mean patient age was 82 years old, and 59% of subjects were male. In most patients, clinical presentation was CF angina III/IV. Patients in the incomplete revascularization group more frequently had multivessel disease. The right coronary artery was treated in 63% of patients. Most coronary procedures were performed before TAVR, and transfemoral access was the primary choice. SAPIEN 3/3 Ultra (37%) and EVOLUT R/PRO/POR+ (37%) were the valves implanted.

Read also: EuroPCR 2022 | GLOBAL SYMPLICITY Registry.

There were no significant differences in the primary endpoints. Furthermore, an analysis of the different subpopulations yielded no differences either.

Conclusion

Complete revascularization in patients who are candidates for TAVR has no impact on the 2-year prognosis, regardless of subpopulation and level of myocardial risk. Therefore, not treating angiographically significant lesions in patients with stable coronary disease who will undergo TAVR would be reasonable.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Management of Myocardial Revascularization in Patients with Stable Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation.

Reference: Giuliano Costa MD. REVASC-TAVI Investigators.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...